Please assess the completion status of the following clinical trial:

Trial Title: A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria - Control Group~1. Have experienced ≥1 episode(s) of MU VOC requiring documented unplanned medical intervention (eg, clinic, physician's office, emergency room or admission) requiring opioid or IV non-steroidal anti-inflammatory drug treatment within 12 months prior to Screening.~2. Participant has no history of past treatment with HU unless the reason for discontinuation was pregnancy (or pregnancy of a partner).~3. Data available for number of MU VOC(s) during the 12-month interval prior to Screening and a value for %HbF collected subsequent to 1 year of age in the absence of recent transfusion.~Inclusion Criteria - HU Treatment Group~1. Have experienced ≥1 episode(s) of MU VOC requiring documented unplanned medical intervention (eg, clinic, physician's office, emergency room or admission) requiring opioid or IV non-steroidal anti-inflammatory drug treatment within12 months prior to initiation of HU.~2. Must be on a stable dose of HU ≥8 weeks prior to Day 1 with the intent of remaining on the same dose throughout the study, unless adjustments are medically necessary due to bone marrow suppression, in accordance with published guidelines.~3. Data available for number of MU VOC(s) during the 12-month interval prior to initiation of HU treatment and a value for %HbF collected subsequent to 1 year of age, prior to initiation of HU treatment and in the absence of recent transfusion.~Exclusion Criteria:~Medical Conditions:~1. Evidence or history of clinically significant hematological (non-SCD), renal, endocrine, pulmonary, gastrointestinal, cardiovascular (including overt stroke but excluding silent cerebral infarct), hepatic (excluding cholelithiasis), psychiatric or neurological disease as assessed from medical records.~2. Participants with any of the following acute or chronic infections or infection history as self-reported and/or assessed from medical records:~   * Fever ≤7 days of Screening;~  * Any infection requiring treatment with anti-infective drug(s) ≤2 weeks ofScreening;~  * COVID-19 infection unless 10 days have elapsed since symptoms first appeared, participant is without symptoms for ≥24 hours and is not experiencing post-COVID-19 symptoms.~3. Marked bone marrow suppression as evidenced by any of the following as per medical record: severe anemia, neutropenia (ANC \<1500 mm3WBC), thrombocytopenia (platelet count \<100,000 mm3) ≤8 weeks of Day 1.~4. Major surgery \<3 months prior to Day 1 as self-reported and/or assessed from medical records or planned significant medical procedures during the study.~5. Females who are pregnant or plan to become pregnant during the study.~6. Other medical or psychiatric condition including cognitive impairment that prevents accurate reporting of pain and/or assessment of SCD symptoms, recent (within the past year) or active suicidal ideation/behavior, or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.~   Prior/Concomitant Therapy:~7. History of hematopoietic stem cell transplant or treatment with gene therapy as assessed from medical records.~8. History of simple transfusion ≤4 weeks of Day 1 as assessed from medical records.Prior/Concurrent Clinical Study Experience:~9. Previous administration with an investigational drug within 30days (or as determined by the local requirement) or 5half-lives preceding Day 1 (whichever is longer).~   Other Exclusions:~10. Active use of illicit drug as determined by the investigator.~    * A history or use of opioids will not be considered an exclusion if participant takes prescribed opioids for pain related to the underlying SCD.~   * A history or use of cannabinoids is not exclusionary.~11. History of alcohol abuse, dependence, or binge drinking within 6months of Screening as determined by the investigator.~    - Binge drinking is defined as a pattern of 5 (male)and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1unit = 8 ounces (240 mL) beer, 1 ounce (30mL) of 40% spirit or 3 ounces (90 mL) of wine).~12. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section (Section 5.3) of this protocol.~13. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.~Lifestyle Considerations:~Investigational drugs are not permitted during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: None): 1. Have experienced ≥1 episode(s) of MU VOC requiring documented unplanned medical intervention (eg, clinic, physician's office, emergency room or admission) requiring opioid or IV non-steroidal anti-inflammatory drug treatment within 12 months prior to Screening.~2. Participant has no history of past treatment with HU unless the reason for discontinuation was pregnancy (or pregnancy of a partner).~3. Data available for number of MU VOC(s) during the 12-month interval prior to Screening and a value for %HbF collected subsequent to 1 year of age in the absence of recent transfusion27(see Inclusion Criteria #2 - All Groups)
- HU Treatment Group (Type: None): 1. Have experienced ≥1 episode(s) of MU VOC requiring documented unplanned medical intervention (eg, clinic, physician's office, emergency room or admission) requiring opioid or IV non-steroidal anti-inflammatory drug treatment within12 months prior to initiation of HU.~2. Must be on a stable dose of HU ≥8 weeks prior to Day 1 with the intent of remaining on the same dose throughout the study, unless adjustments are medically necessary due to bone marrow suppression, in accordance with published guidelines.~3. Data available for number of MU VOC(s) during the 12-month interval prior to initiation of HU treatment and a value for %HbF collected subsequent to 1 year of age, prior to initiation of HU treatment and in the absence of recent transfusion27(see Inclusion Criteria #2 - All Groups).

Based on this trial design, predict the completion outcome and termination type (if applicable).